Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017025712 - USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY

Publication Number WO/2017/025712
Publication Date 16.02.2017
International Application No. PCT/GB2016/052340
International Filing Date 29.07.2016
IPC
A61K 31/05 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 36/185 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
CPC
A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
A61K 31/192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
192having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
A61K 36/185
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
08Antiepileptics; Anticonvulsants
Applicants
  • GW PHARMA LIMITED [GB]/[GB]
Inventors
  • STOTT, Colin
  • JONES, Nicholas
  • WILLIAMS, Robin
  • WHALLEY, Benjamin
Agents
  • HGF LIMITED
Priority Data
1514079.110.08.2015GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
(FR) UTILISATION DE CANNABINOÏDES DANS LE TRAITEMENT DE L'ÉPILEPSIE
Abstract
(EN)
The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.
(FR)
La présente invention concerne l'utilisation d'une quantité thérapeutiquement efficace d'acide cannabidiolique (CBDA) dans le traitement de l'épilepsie. Dans un mode de réalisation, le CBDA est utilisé dans le traitement de crises généralisées, de préférence des crises tonico-cloniques. De préférence, le CBDA utilisé se présente sous la forme d'une substance médicamenteuse d'origine végétale dont le contenu en CBDA est supérieur à 60 %, et plus préférablement, il s'agit d'un extrait hautement purifié de cannabis, tel que le CBDA est présent en une quantité supérieure à 95 %, en passant par des valeurs de 96 % et 97 % jusqu'à des valeurs, de beaucoup préférées, supérieures à 98 % en poids de l'extrait total, et les autres composants de l'extrait sont caractérisés. En particulier, les cannabinoïdes tétrahydrocannabinol (THC) ou acide tétrahydrocannabinolique (THCA) ont été en grande partie éliminés. Dans un autre mode de réalisation, le CBDA peut être produit par synthèse.
Latest bibliographic data on file with the International Bureau